Trait
Malignant hyperthermia
Malignant hyperthermia is characterized by a rapid increase in temperature to 39-42 degrees C. Malignant hyperthermia may occur in response to either inhalational anesthetics such as halothane, to muscle relaxants such as succinylcholine, or to exercise.
Summary
- Body system
- Laboratory abnormality
Reference genomeGRCh38hg38
Positions on gene and variant pages follow this choice, in this browser.
Read the genes linked to Malignant hyperthermia, and the rest of your genome, with one test.
From $449Free shipping · Results in 6–8 weeks
Get my Genome Test28 genes linked to Malignant hyperthermia
Changes in these genes cause rare conditions in which Malignant hyperthermia is seen. Most people with this trait have none of those conditions, and a gene on this list says nothing about anyone's own genome.
| Gene | How often it is seen | Conditions |
|---|---|---|
| ATP2A1ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 | Always | In 1 condition |
| SCO2synthesis of cytochrome C oxidase 2 | Always | In 1 condition |
| CLCF1cardiotrophin like cytokine factor 1 | Very often (80–99%) | In 1 condition |
| CRLF1cytokine receptor like factor 1 | Very often (80–99%) | In 1 condition |
| ELP1elongator acetyltransferase complex subunit 1 | Very often (80–99%) | In 1 condition |
| RYR1ryanodine receptor 1 | Very often (80–99%) | In 8 conditions |
| TRAPPC9trafficking protein particle complex subunit 9 | Very often (80–99%) | In 1 condition |
| CACNA1Scalcium voltage-gated channel subunit alpha1 S | Often (30–79%) | In 2 conditions |
| MYH3myosin heavy chain 3 | Often (30–79%) | In 2 conditions |
| NALCNsodium leak channel, non-selective | Often (30–79%) | In 1 condition |
| STAC3SH3 and cysteine rich domain 3 | Often (30–79%) | In 2 conditions |
| ABCA12ATP binding cassette subfamily A member 12 | Sometimes (5–29%) | In 1 condition |
| EDARectodysplasin A receptor | Sometimes (5–29%) | In 1 condition |
| EDARADDEDAR associated via death domain | Sometimes (5–29%) | In 1 condition |
| HSPG2heparan sulfate proteoglycan 2 | Sometimes (5–29%) | In 2 conditions |
| KDF1keratinocyte differentiation factor 1 | Sometimes (5–29%) | In 1 condition |
| LRP6LDL receptor related protein 6 | Sometimes (5–29%) | In 1 condition |
| PGM1phosphoglucomutase 1 | Sometimes (5–29%) | In 1 condition |
| SCN4Asodium voltage-gated channel alpha subunit 4 | Sometimes (5–29%) | In 1 condition |
| TRAF6TNF receptor associated factor 6 | Sometimes (5–29%) | In 1 condition |
| BIN1bridging integrator 1 | Rarely (1–4%) | In 1 condition |
| DNM2dynamin 2 | Rarely (1–4%) | In 1 condition |
| MTMR14myotubularin related protein 14 | Rarely (1–4%) | In 1 condition |
| MYF6myogenic factor 6 | Rarely (1–4%) | In 1 condition |
| CHRNA1cholinergic receptor nicotinic alpha 1 subunit | Not recorded | In 1 condition |
| CHRNDcholinergic receptor nicotinic delta subunit | Not recorded | In 1 condition |
| CHRNGcholinergic receptor nicotinic gamma subunit | Not recorded | In 1 condition |
| SCN5Asodium voltage-gated channel alpha subunit 5 | Not recorded | In 1 condition |
How often is among people with one of the gene's conditions, the most often across them, as the Human Phenotype Ontology records it. These pages describe traits and the research behind them; they are not a diagnosis, and a doctor or genetic counsellor is the person to ask about symptoms.
Broader traits
Where this comes from
- The Human Phenotype Ontology, release 2026-09-01: the trait, its names, its definition and the genes linked to it. Find out more at hpo.jax.org.
- Data release 2026.10.16-c6eea6bf.
One test. A lifetime of answers.
From $449Free shipping · Results in 6–8 weeks